Denali expects $30M-$32M Q4 AVLAYAH net product revenue as Sanfilippo BLA filing remains planned for 2027 (NASDAQ:DNLI)

Denali Therapeutics Q3 2026 earnings: AVLAYAH sales beat expectations, Q4 revenue outlook rose, and key 2027 pipeline milestones sharpen.

Continue in Briflio to read, react, comment, and share.